OmniInsight™ for Prostate Cancer (OI-PC™) (PRS + Monogenic)

OmniInsight™ for Prostate Cancer (OI-PC™) (PRS + Monogenic)

$1,900.00

A Breakthrough Saliva Genetic Test for Predicting Prostate Cancer Risk

OmniInsight™ for Prostate Cancer is an advanced saliva-based genetic test that evaluates your inherited risk for prostate cancer by analyzing both Polygenic Risk Scores (PRS) and Monogenic Mutations.
The test examines clinically significant and actionable genes associated with prostate cancer and integrates them with a Multi-Ancestry Prostate Cancer PRS to deliver a comprehensive and precise genetic risk estimate tailored to each individual.

Results in 4–8 weeks

Test Highlights:

  • PRS Indication: Prostate Cancer
  • Monogenic Genes: BRCA1, BRCA2, ATM, PALB2, CHEK2, HOXB13, MLH1, MSH2, MSH6, PMS2
  • Comprehensive Risk Report: Personalized interpretation of your genetic findings and risk level
  • Free Virtual Consultation: One-on-one session with a certified genetic counselor to review your results and discuss personalized prevention strategies

Price Includes:
A complete Comprehensive Genomic Risk Test, including your individualized risk report, genetic counseling for individuals with above-average or high risk, and a personalized prevention roadmap to support early detection and informed health decisions.

Exclusive Access:
Gain access to Avigena’s OmniInsight™ (OI™) Integrated Genomic Intelligence Platform, which combines Monogenic and Polygenic Risk Scores (PRS) with clinical and lifestyle data to deliver a holistic, personalized risk assessment and actionable prevention strategy.

Code: AVI-OI-PC™ Category:

"Prevent Prostate Cancer."

Simple DNA Saliva To Uncover Your Inherited Risk For Prostate Cancer

Validated across diverse ancestry and tailored to the Arab and Middle Eastern population

What Is A Polygenic Score?

  • Everyone has small genetic differences, called variants.
  • These variants can affect the risk of developing certain diseases.
  • A polygenic risk score (PRS) combines the effects of millions of genetic variants to estimate your disease risk.
  • While each variant has a small effect, their combined impact can be significant.
Know More

Who Should Tale This Test?

Healthy Men aged 40 and above interested in understanding their genetic risk

Men with a family history of prostate cancer (especially first-degree relatives)

Men of African or Middle Eastern ancestry, who are at higher genetic risk and underrepresented in traditional screening tools

Men with known monogenic mutations (e.g., BRCA1/2, HOXB13) seeking a more comprehensive risk assessment

Men with elevated PSA levels or inconclusive biopsy results, as part of a broader risk evaluation

Men at average risk considering when and how often to begin screening

Why PRS Matters For Prostate Cancer

Personalized Risk: PRS provides an individualized estimate of lifetime prostate cancer risk based on common genetic variants.

Beyond Family History: It identifies risk in men without a known family history or monogenic mutation.

Stronger Stratification: PRS complements PSA and family history, helping distinguish between low-, intermediate-, and high-risk individuals.

Early Detection: Guides earlier and more frequent screening in high-risk individuals, potentially enabling timely diagnosis and treatment.

Precision Prevention: Informs lifestyle counseling and preventive strategies tailored to genetic risk.

Better Resource Use: Helps reduce over-screening in low-risk men and focus healthcare resources on those most at risk.

How It Works - Step By Step

The test is powered by the innovative Blended Genome Exome™ technology, developed in collaboration with Broad Clinical Labs at Harvard University and the Massachusetts Institute of Technology.

The technology combines 95.5× whole-exome sequencing (WES) with genome-wide low-coverage whole-genome sequencing (lcWGS) to detect both rare pathogenic variants and polygenic risk with high analytical precision.

Testing is performed through CAP/CLIA accredited laboratories, with advanced analytics support from Allelica and the Laboratory for Molecular Medicine (Mass General Brigham), and regional collaboration with Novo Genomics.

 

Order Now

Equipped with one of the most precise and comprehensive genomic risk assessments available, the test integrates monogenic and polygenic risk into a single, clinically actionable report.

Results are ready in 4 to 8 weeks, enabling you to act early and make informed, proactive health decisions. 

[email protected]